Benzinga Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026. read more